tbuckley/cabot-search huggingface dataset:
Biomarkers for monitoring clinical efficacy of allergen immunotherapy for allergic rhinoconjunctivitis and allergic asthma: an EAACI Position Paper
Authors: M. H. Shamji, J. H. Kappen, M. Akdis, E. Jensen‐Jarolim, E. F. Knol, J. Kleine‐Tebbe, B. Bohle, A. M. Chaker, S. J. Till, R. Valenta, L. K. Poulsen, M. A. Calderon, P. Demoly, O. Pfaar, L. Jacobsen, S. R. Durham, C. B. Schmidt‐Weber
Journal: Allergy (2017)

Allergen immunotherapy (AIT) is an effective treatment for allergic rhinoconjunctivitis (AR) with or without asthma. It is important to note that due to the complex interaction between patient, allergy triggers, symptomatology and vaccines used for AIT, some patients do not respond optimally to the treatment. Furthermore, there are no validated or generally accepted candidate biomarkers that are predictive of the clinical response to AIT. Clinical management of patients receiving AIT and efficacy in randomised controlled trials for drug development could be enhanced by predictive biomarkers.The EAACI taskforce reviewed all candidate biomarkers used in clinical trials of AR patients with/without asthma in a literature review. Biomarkers were grouped into seven domains: (i) IgE (total IgE, specific IgE and sIgE/Total IgE ratio), (ii) IgG-subclasses (sIgG1, sIgG4 including SIgE/IgG4 ratio), (iii) Serum inhibitory activity for IgE (IgE-FAB and IgE-BF), (iv) Basophil activation, (v) Cytokines and Chemokines, (vi) Cellular markers (T regulatory cells, B regulatory cells and dendritic cells) and (vii) In vivo biomarkers (including provocation tests?).All biomarkers were reviewed in the light of their potential advantages as well as their respective drawbacks. Unmet needs and specific recommendations on all seven domains were addressed.It is recommended to explore the use of allergen-specific IgG4 as a biomarker for compliance. sIgE/tIgE and IgE-FAB are considered as potential surrogate candidate biomarkers. Cytokine/chemokines and cellular reponses provided insight into the mechanisms of AIT. More studies for confirmation and interpretation of the possible association with the clinical response to AIT are needed.
CD73/NT5E is a target of miR-30a-5p and plays an important role in the pathogenesis of non-small cell lung cancer
Authors: Jianjie Zhu, Yuanyuan Zeng, Wei Li, Hualong Qin, Zhe Lei, Dan Shen, Dongmei Gu, Jian-an Huang, Zeyi Liu
Journal: Molecular Cancer (2017)

CD73 (ecto-5′-nucleotidase) is implicated in the development of many types of cancer. CD73 inhibitors are currently being tested in clinical trials for the treatment of cancer. Understanding the molecular and cellular actions of CD73 inhibitors is the key to improving this line of therapy. Quantitative real-time PCR (qRT-PCR) was used to detect the expression of CD73 and miR-30a-5p; Western blot and immunohistochemical assays were used to investigate the levels of CD73 and other proteins. Flow cytometry was used to determine cell cycle stage and apoptosis. CCK-8 and clonogenic assays were used to investigate cell proliferation. Wound healing, migration and invasion assays were used to investigate the motility of cells. A lung carcinoma xenograft mouse model was used to investigate the in vivo effects of CD73 and miR-30a-5p. In the present study, we found that CD73 is overexpressed and miR-30a-5p is underexpressed in non-small cell lung cancer tissues compared with adjacent noncancerous. Further, we showed that CD73 is a direct target of miR-30a-5p by luciferase reporter assays, qRT-PCR and western blot analysis. We also found that overexpression of miR-30a-5p in these non-small cell lung cancer cell lines inhibited cell proliferation in vitro and in vivo. Moreover, the epithelial-to-mesenchymal phenotype was suppressed and cell migration and invasion were inhibited; these effects were brought about via the EGF signaling pathway. Our findings reveal a new post-transcriptional mechanism of CD73 regulation via miR-30a-5p and EGFR-related drug resistance in non-small cell lung cancer.
Reduced intensity conditioning with combined haploidentical and cord blood transplantation results in rapid engrafment and durable remissions.
Authors: K. Van Besien, H. Liu, E. S. Rich, L. A. Godley, O. Odenike, L. Joseph, J. P. Kline, V. H. Nguyen, J. M. Cunningham, R. A. Larson, W. Stock, A. Wickrema, A. S. Artz
Journal: Journal of Clinical Oncology (2011)

6525 Background: Transplantation of CD34+ stem cells from a haploidentical family member plus a cord blood (UCB) unit is a promising approach for patients (pts) who lack HLA donors that facilitates early engraftment while preserving long-term cord blood reconstitution. Methods: We prospectively investigated this approach in combination with reduced intensity conditioning consisting of fludarabine, melphalan and ATG in 39 patients with high-risk hematological malignancies from January 29, 2007 to November 12, 2010. Median age was 48 yrs (20-69); 24 (62%) had active disease at transplant. 12 pts belonged to ethnic minorities. Results: The median haploidentical donor CD34+ dose was 3.08 x 106/kg (1.0-11); CD3+ cells were 0.8 x 104/kg (0.03-2.4). Median UCB nucleated cell dose was 1.55 x 107/kg (range, 0.86-5.23); CD34+ cells were 0.06 x 106/kg (0.02-0.75). 37 (95%) pts had neutrophil recovery with a median time to ANC >500/mL of 11 days (9-43). 27 (69%) pts became platelet transfusion independent at median time of 19.5 days (10-132). In the majority of pts, early haploidentical engraftment was replaced by durable engraftment of UCB by 100 days. However, 5 pts had persistent haploidentical only chimerism, while 4 pts had delayed engraftment with only UCB. Acute GVHD grade II-IV occurred in 10 pts (26%) with only 2 Grade III GVHD (5%). Day 100 mortality rate was 21%. With a median follow up for survivors of 298 days (89-1133), 19 pts (49%) are currently alive. 8 pts died from disease relapse, 4 from infection, and 3 from graft failure. For the entire cohort 1 yr OS was 47% and PFS 38%. For pts in CR at SCT 1 yr PFS was 63% and OS 70%. For pts with active disease at SCT 1 yr OS and PFS were 37%. Conclusions: Combined haploidentical donor and UCB transplantation in the large majority of patients results in rapid neutrophil engraftment due to the haplo-identical progenitor cells. Durable engraftment is provided by the UCB graft with a low rate of GVHD and excellent long term disease control, even in patients with active disease at transplant.
Loss of Expression of the Pro-Apoptotic Bcl-2 Family Proteins Bak and Bax in Rituximab- and Chemotherapy-Resistant Non-Hodgkin’s Lymphoma Cells.
Authors: Scott H. Olejniczak, Francisco J. Hernandez-Ilizaliturri, James L. Clements, Myron S. Czuczman
Journal: Blood (2005)
Quantitation of EBV-DNA In Peripheral Blood In Hodgkin Lymphoma: Associations with Other Biomarkers and Patient Characteristics
Authors: Stefan Hohaus, Manuela Giachelia, Barabara Vannata, Rosaria Santangelo, Maurizio Martini, Tonia Cenci, Giuseppina Massini, Annarosa Cuccaro, D'Alo Francesco, Maria Teresa Voso, Giovanni Fadda, Luigi Larocca, Giuseppe Leone
Journal: Blood (2010)
An Elevated Tricuspid Regurgitant Jet Velocity in Sickle Cell Disease Is Associated with Polymorphisms in Genes Impacting Innate Immunity
Authors: Harold T. Bae, Clinton T. Baldwin, Mark T Gladwin, Allison E Ashley-Koch, Melanie Garrett, Karen Soldano, James G. Taylor, Gregory J. Kato, Marilyn J. Telen, Paola Sebastiani, Martin H. Steinberg, Elizabeth S Klings
Journal: Blood (2011)
Erratum. The Use of Anthropometric Measures for Cardiometabolic Risk Identification in a Rural African Population. Diabetes Care 2013;37:e64–e65
Authors: Georgina A.V. Murphy, Gershim Asiki, Rebecca N. Nsubuga, Elizabeth H. Young, Janet Seeley, Manjinder S. Sandhu, Anatoli Kamali
Journal: Diabetes Care (2017)

In the article listed above, there was an omission from the byline of author Dermot Maher. Dr. Maher’s name …
Association of Therapy for Autoimmune Disease With Myelodysplastic Syndromes and Acute Myeloid Leukemia
Authors: Natalie Ertz-Archambault, Heidi Kosiorek, Gretchen E. Taylor, Katalin Kelemen, Amylou Dueck, Janna Castro, Robert Marino, Susanne Gauthier, Laura Finn, Lisa Z. Sproat, Jeanne Palmer, Ruben A. Mesa, Aref Al-Kali, James Foran, Raoul Tibes
Journal: JAMA Oncology (2017)

Therapy-related myeloid neoplasms are a potentially life-threatening consequence of treatment for autoimmune disease (AID) and an emerging clinical phenomenon.To query the association of cytotoxic, anti-inflammatory, and immunomodulating agents to treat patients with AID with the risk for developing myeloid neoplasm.This retrospective case-control study and medical record review included 40 011 patients with an International Classification of Diseases, Ninth Revision, coded diagnosis of primary AID who were seen at 2 centers from January 1, 2004, to December 31, 2014; of these, 311 patients had a concomitant coded diagnosis of myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML). Eighty-six cases met strict inclusion criteria. A case-control match was performed at a 2:1 ratio.Odds ratio (OR) assessment for AID-directed therapies.Among the 86 patients who met inclusion criteria (49 men [57%]; 37 women [43%]; mean [SD] age, 72.3 [15.6] years), 55 (64.0%) had MDS, 21 (24.4%) had de novo AML, and 10 (11.6%) had AML and a history of MDS. Rheumatoid arthritis (23 [26.7%]), psoriasis (18 [20.9%]), and systemic lupus erythematosus (12 [14.0%]) were the most common autoimmune profiles. Median time from onset of AID to diagnosis of myeloid neoplasm was 8 (interquartile range, 4-15) years. A total of 57 of 86 cases (66.3%) received a cytotoxic or an immunomodulating agent. In the comparison group of 172 controls (98 men [57.0%]; 74 women [43.0%]; mean [SD] age, 72.7 [13.8] years), 105 (61.0%) received either agent (P = .50). Azathioprine sodium use was observed more frequently in cases (odds ratio [OR], 7.05; 95% CI, 2.35- 21.13; P < .001). Notable but insignificant case cohort use among cytotoxic agents was found for exposure to cyclophosphamide (OR, 3.58; 95% CI, 0.91-14.11) followed by mitoxantrone hydrochloride (OR, 2.73; 95% CI, 0.23-33.0). Methotrexate sodium (OR, 0.60; 95% CI, 0.29-1.22), mercaptopurine (OR, 0.62; 95% CI, 0.15-2.53), and mycophenolate mofetil hydrochloride (OR, 0.66; 95% CI, 0.21-2.03) had favorable ORs that were not statistically significant. No significant association between a specific length of time of exposure to an agent and the drug's category was observed.In a large population with primary AID, azathioprine exposure was associated with a 7-fold risk for myeloid neoplasm. The control and case cohorts had similar systemic exposures by agent category. No association was found for anti-tumor necrosis factor agents. Finally, no timeline was found for the association of drug exposure with the incidence in development of myeloid neoplasm.
Thrombelastographic Whole Blood Coagulation Parameters Demonstrate Improved Clot Strength Induced by Tranexamic Acid during Cardiopulmonary Bypass.
Authors: Benny Sørensen, Thomas D. Christensen, Mogens Harrits Jepsen, Lars Folkersen, Inge Severinsen, Vibeke E. Hjortdal, Jørgen Ingerslev
Journal: Blood (2007)
Pre-Emptive Therapy with Modified Donor Lymphocyte Infusion Could Reduce Relapse and Improve Survival in Standard-Risk Acute Leukemia Patients After Allogeneic Hematopoietic Stem Cell Transplantation
Authors: Chenhua Yan, Daihong Liu, Lanping Xu, Kaiyan Liu, Huan Chen, Wei Han, Yu Wang, Xiaojun Huang
Journal: Blood (2011)
Intrapericardial Left Ventricular Assist Device for Advanced Heart Failure
Authors: Joseph G. Rogers, Francis D. Pagani, Antone J. Tatooles, Geetha Bhat, Mark S. Slaughter, Emma J. Birks, Steven W. Boyce, Samer S. Najjar, Valluvan Jeevanandam, Allen S. Anderson, Igor D. Gregoric, Hari Mallidi, Katrin Leadley, Keith D. Aaronson, O.H. Frazier, Carmelo A. Milano
Journal: New England Journal of Medicine (2017)

Mechanical circulatory support with a left ventricular assist device (LVAD) is an established treatment for patients with advanced heart failure. We compared a newer LVAD design (a small intrapericardial centrifugal-flow device) against existing technology (a commercially available axial-flow device) in patients with advanced heart failure who were ineligible for heart transplantation.
Serum Soluble Syndecan-1 Levels Correlate with Erythropoietin and Inversely with Hemoglobin Levels in Untreated Anaemic Myeloma Patients: Possible Role of Syndecan-1 in the Mechanisms of Chronic Anaemia.
Authors: Marie-Christine Kyrtsonis, Theodoros P. Vassilakopoulos, Argyro Papadogiannis, Tatiana Tzenou, Maria N. Dimopoulou, Marina P. Siakantaris, Styliani I. Kokoris, Evangelia Dimitriadou, Maria K. Angelopoulou, Christine Kalpadaki, Gerassimos A. Pangalis
Journal: Blood (2004)
TMIC-05DCE-MR PHARMACOKINETIC MODEL EVOLUTION TECHNIQUE FOR PREDICTION OF INTERSTITIAL FLUID PRESSURE IN EMBEDDED TUMORS
Authors: Hassan Bagher-Ebadian, Azimeh N.V. Dehkordi, Rasha Alamgharibi, Tavarekere Nagaraja, David Nathanson, Hamid Soltanian-Zadeh, Stephen Brown, Hamed Moradi, Ali S. Arbab, James R. Ewing
Journal: Neuro-Oncology (2015)
In Vivo Drug-Response in Patients with Leukemic Non-Hodgkin’s Lymphomas Is Predicted by In Vitro Chemosensitivity Testing and Gene Expression Profiling.
Authors: Kai Uwe Chow, Daniel Nowak, Soo-Zin Kim, Bernd Schneider, Martina Komor, Simone Boehrer, Paris S. Mitrou, Dieter Hoelzer, Eckhart Weidmann, Wolf-Karsten Hofmann
Journal: Blood (2004)
Oligonucleotide Microarray Analysis of Ocular Adnexal MALT Lymphoma with Trisomy 18.
Authors: Naohiro Sekiguchi, Kazuki Tanimoto, Tsutomu Ohta, Junko Nomoto, Yukiko Yokota, Sung-Wong Kim, Takashi Watanabe, Akiko Maeshima, Yoshihiro Matsuno, Kensei Tobinai, Yukio Kobayashi
Journal: Blood (2006)
3D, a Novel Mutation That Confers Defective Sensing by Toll-Like Receptors 3, 7 and 9.
Authors: Koichi Tabeta, Xin Du, Georgel Philippe, Kasper Hoebe, Navjiwan Mann, Suzanne Mudd, Nanni Huser, Louis Shamel, Karine Crozat, Lisa Tarantino, Michael Cooke, Bruce Beutler
Journal: Blood (2004)
Exogenous vitamin C boosts the antitumor efficacy of paclitaxel containing reduction-sensitive shell-sheddable micelles in vivo
Authors: Yaqin Zhu, Xiuxiu Wang, Jian Zhang, Fenghua Meng, Chao Deng, Ru Cheng, Jan Feijen, Zhiyuan Zhong
Journal: Journal of Controlled Release (2017)
Detection of BCR-ABL Transcript by Quantitative Real-Time PCR and Amp-CML (Transcript Mediated Amplification) during Imatinib Therapy for Chronic Myeloid Leukemia.
Authors: Koichi Miyamura, Fumiharu Yagasaki, Taiichi Kyo, Kazunori Ohnishi, Tomoki Naoe, Hitoshi Takeuchi, Miki Nishimura, Shin Fujiwara, Tetsuzo Tauchi, Ryuzo Ohno
Journal: Blood (2006)
Relevance and Factors Predicting for Early Lymphocyte Recovery After Allogeneic Bone Marrow Stem Cell Transplantation (BMT).
Authors: Ulas D. Bayraktar, Rima M Saliba, Gabriela Rondon, Antonio Di Stasi, Partow Kebriaei, Marcos de Lima, Richard E. Champlin, Stefan O. Ciurea
Journal: Blood (2012)
IL-33–Mediated Expansion of Type 2 Innate Lymphoid Cells Protects from Progressive Glomerulosclerosis
Authors: Jan-Hendrik Riedel, Martina Becker, Kerstin Kopp, Mathis Düster, Silke R. Brix, Catherine Meyer-Schwesinger, Luis A. Kluth, Ann-Christin Gnirck, Madena Attar, Sonja Krohn, Boris Fehse, Rolf A.K. Stahl, Ulf Panzer, Jan-Eric Turner
Journal: Journal of the American Society of Nephrology (2017)

Innate lymphoid cells (ILCs) have an important role in the immune system's response to different forms of infectious and noninfectious pathologies. In particular, IL-5– and IL-13–producing type 2 ILCs (ILC2s) have been implicated in repair mechanisms that restore tissue integrity after injury. However, the presence of renal ILCs in humans has not been reported. In this study, we show that ILC populations are present in the healthy human kidney. A detailed characterization of kidney-residing ILC populations revealed that IL-33 receptor–positive ILC2s are a major ILC subtype in the kidney of humans and mice. Short-term IL-33 treatment in mice led to sustained expansion of IL-33 receptor–positive kidney ILC2s and ameliorated adriamycin-induced glomerulosclerosis. Furthermore, the expansion of ILC2s modulated the inflammatory response in the diseased kidney in favor of an anti-inflammatory milieu with a reduction of pathogenic myeloid cell infiltration and a marked accumulation of eosinophils that was required for tissue protection. In summary, kidney-residing ILC2s can be effectively expanded in the mouse kidney by IL-33 treatment and are central regulators of renal repair mechanisms. The presence of ILC2s in the human kidney tissue identifies these cells as attractive therapeutic targets for CKD in humans.
First Multicenter, Randomized Phase 3 Study in Patients (Pts) with Relapsed/Refractory (R/R) Peripheral T-Cell Lymphoma (PTCL): Alisertib (MLN8237) Versus Investigator's Choice (Lumiere trial; NCT01482962)
Authors: Owen A. O'Connor, Muhit Özcan, Eric D. Jacobsen, Josep Maria Roncero Vidal, Judith Trotman, Judit Demeter, Tamás Masszi, Juliana Pereira, Radhakrishnan Ramchandren, Francesco A. d'Amore, Francine Foss, Won-Seog Kim, John P. Leonard, Carlos Sérgio Chiattone, Pier Luigi Zinzani, Hua Liu, JungAh Jung, Xiaofei Zhou, E. Jane Leonard, Claudio Dansky Ullmann, Andrei R. Shustov
Journal: Blood (2015)
Loss of p16 INK4A Expression and Homozygous CDKN2A Deletion Are Associated with Worse Outcome and Younger Age in Thymic Carcinomas
Authors: Scott W. Aesif, Marie Christine Aubry, Eunhee S. Yi, Sara M. Kloft-Nelson, Sarah M. Jenkins, Grant M. Spears, Patricia T. Greipp, William R. Sukov, Anja C. Roden
Journal: Journal of Thoracic Oncology (2017)
Comprehensive HOX Gene Expression Profiles Are Associated with Major Cytogenetic Prognostic Categories in AML.
Authors: Harry A. Drabkin, Vivian Ruvolo, Sharvari Gadgil, Wenjing Chen, Chan Zeng, Anna E. Baron, Steven M. Kornblau, Elihu Estey, Kevin R. Coombes, Michael Andreeff
Journal: Blood (2005)
Diagnostic and Prognostic Implications of Spine Magnetic Resonance Imaging At Diagnosis in Patients with Multiple Myeloma
Authors: Ik-Chan Song, Kyu-Seop Lee, Hae-Won Ryu, Myung-Won Lee, Hyo-Jin Lee, Hwan-Jung Yun, Soon-Tae Kwon, Samyong Kim, Deog-Yeon Jo
Journal: Blood (2012)
Study on the Hepatic Circulation : Part I : A Method for the Measurement of the Ratio of Hepatic Arterial and Portal Flow with the Electric Conductivity Method
Authors: Hitoshi Matsuno
Journal: Circulation (1969)

The theory and the procedure for the measurement of the ratio of hepatic arterial and portal flow with the method of electroconductivity, using saline as an indicator were reported. The ratio of hepatic arterial and portal flow of healthy dogs was 16.5±10 : 83.5±10 in average. And then studies were performed the hepatic circulation in hypoxic state and experimental pulmonary embolism of dogs. In hypoxic state, the portal flow was increased remarkably with the ratio of hepatic arterial flow decreased. In pulmonary embolism, increased hepatic arterial flow and decreased portal blood flow were demonstrated.
Age and menopausal effects of hormonal birth control and hormone replacement therapy in relation to breast cancer risk
Authors: Sumitra Shantakumar, Mary Beth Terry, Andrea Paykin, Susan L. Teitelbaum, Julie A. Britton, Patricia G. Moorman, Stephen B. Kritchevsky, Alfred I. Neugut, Marilie D. Gammon
Journal: Cancer Research (2006)

466  Context It is unclear whether the effects of hormonal birth control (HBC) and hormone replacement therapy (HRT) on breast cancer risk, taken either singly or cumulatively, vary over the lifecourse. Objectives To determine the age- and menopausal-specific effects of exogenous hormone use on breast cancer risk. Specifically, to investigate potential latency effects of prior HBC use in older postmenopausal women, to characterize the effect of HRT use in premenopausal women, and to determine if the combined use of HBC and HRT is more detrimental than use of either singly. Design, Setting, and Patients Population-based case-control study that included 1508 breast cancer cases and 1556 controls ages 20 to 98 years who completed an in-home interviewer-administered questionnaire. Main Outcome Measure Effect of HBC use and HRT use on breast cancer risk, stratified by age and menopausal status: premenopausal women (n=968), postmenopausal women   5 years of HRT use (OR=1.41, 95% CI= 1.00, 1.99). The estimates of effect for HBC or HRT use were close to the null among postmenopausal women ≥ 65 years. Conclusion These results emphasize the importance of timing, recency, duration and dual use of exogenous hormones on breast cancer risk over the lifecourse, as women who used these hormones before menopause had elevated risks, but the pronounced, harmful effects began to decline with age after menopause.
Deficiency of Mannose-Binding Lectin Is a Risk Factor for Invasive Pulmonary Aspergillosis in Patients with Multiple Myeloma: An Analysis of 482 Patients
Authors: Elias J. Anaissie, Wei-zhi Zhao, Yue-Jin Wen, Monica Grazziutti, Wen Ling, Jeanette Lee, Frits van Rhee, Bart Barlogie
Journal: Blood (2008)
Abstract #2281: The PDZ LIM protein PDLIM2/Mystique is essential for polarized migration of prostate carcinoma cells
Authors: Rachael Bowe, Nollaig Healy, Orla Cox, Rosemary O'Connor
Journal: Cancer Research (2009)

AACR Annual Meeting-- Apr 18-22, 2009; Denver, CO

PDLIM2 (also known as Mystique) is a PDZ-LIM domain containing protein that associates with the actin cytoskeleton. It is expressed in the nucleus where it can promote the degradation of the transcription factors NF\#954;B and STATs in hemopoietic cells. We have previously shown that PDLIM2 is required for epithelial cell attachment and migration; however the mechanism of PDLIM2 action at the cytoskeleton remains unknown. The objective of this study was to investigate this mechanism, using the DU145 androgen-independent human prostate carcinoma cell line, which expresses high levels of PDLIM2. DU145 cells stably expressing a specific short hairpin RNA (shRNA) targeting the PDLIM2 gene (DU145-shPDLIM2) or expressing a control shRNA was generated. Cell adhesion, migration, and integrin-mediated signalling were then investigated in these cells. DU145-shPDLIM2 cells had decreased ability to spread upon contact with extracellular matrix proteins, but displayed increased adhesive strength compared with control cells. In live cell imaging assays cell with suppressed PDLIM2 had greatly impaired directional cell migration, and could not fill in wounds in monolayer culture. Impaired actin cytoskeleton reorganization after wounding was observed. Cells appeared less polarized and displayed extended protrusions in multiple directions to support random movement. DU145-shPDLIM2 cells apparently could not \#8220;sense\#8221; the wound and orient their MicroTubule Organizing Centres (MTOCs) because MTOCs polarized in the direction of the wound were not evident. Increased phosphorylation of Cofilin which prevents actin cytoskeleton reorganization and polarization was also observed in these cells after wounding. DU145-shPDLIM2 proliferated faster in monolayer culture than controls, although they could not form colonies in soft agarose. Increased \#946;1 integrin expression (mRNA and protein) accompanied by increased tyrosine phosphorylation of Focal Adhesion Kinase was observed. This increase in integrin signalling is consistent with decreased cell motility and increased cell adhesion. Overall these data indicate that PDLIM2 is required for directional cell migration, cell polarization and anchorage-independent growth in DU145 cells and suggest that PDLIM2 may mediate these effects through regulation of \#946;1 integrin expression and integrin-dependent signaling.

Citation Information: In: Proc Am Assoc Cancer Res; 2009 Apr 18-22; Denver, CO. Philadelphia (PA): AACR; 2009. Abstract nr 2281.